Checkpoint Therapeutics: Funding, Investors & Team (Sep 2026)
Checkpoint Therapeutics primarily focuses on progressing the development of cancer immunotherapy and targeted oncology treatments. The company is committed to expediting the process of bringing cancer therapies to market and actively seeks out opportunities to acquire, license, or co-develop products that align with its areas of specialization. By implementing a streamlined approach, Checkpoint Therapeutics reduces risk and speeds up the development and introduction of oncology drugs, ultimately ensuring that more patients, payors, and providers have access to effective and affordable treatment options.
Checkpoint Therapeutics has raised $22.0M across 2 funding rounds on record, the most recent an undisclosed round of $12.0M announced in Jul 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Checkpoint Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Checkpoint Therapeutics Funding Rounds
Checkpoint Therapeutics raised $10.0M in an undisclosed round announced in May 2023.
1.2 years later, an undisclosed round of $12.0M was announced in Jul 2024.
Checkpoint Therapeutics Founders and Leadership Team
Contact details for the Checkpoint Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Checkpoint Therapeutics Funding Compared to Other Biotechnology Startups
Checkpoint Therapeutics' latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Checkpoint Therapeutics in Biotechnology and Waltham
Companies Similar to Checkpoint Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Checkpoint Therapeutics Funding FAQs
What does Checkpoint Therapeutics do?
Checkpoint Therapeutics primarily focuses on progressing the development of cancer immunotherapy and targeted oncology treatments. The company is committed to expediting the process of bringing cancer therapies to market and actively seeks out opportunities to acquire, license, or co-develop products that align with its areas of specialization. By implementing a streamlined approach, Checkpoint Therapeutics reduces risk and speeds up the development and introduction of oncology drugs, ultimately ensuring that more patients, payors, and providers have access to effective and affordable treatment options.
How much funding has Checkpoint Therapeutics raised?
Checkpoint Therapeutics has raised $22.0M across 2 rounds on record. The most recent is an undisclosed round of $12.0M announced in Jul 2024.
When did Checkpoint Therapeutics last raise funding?
Checkpoint Therapeutics' most recent funding round on record is an undisclosed round of $12.0M, announced in Jul 2024.
Who founded Checkpoint Therapeutics?
FundedIQ lists James Oliviero (Founder) at Checkpoint Therapeutics.
Who is the CEO of Checkpoint Therapeutics?
James F Oliviero is listed as CEO at Checkpoint Therapeutics.
Where is Checkpoint Therapeutics headquartered?
Checkpoint Therapeutics is based in Waltham, Massachusetts, United States.
How many employees does Checkpoint Therapeutics have?
Checkpoint Therapeutics is in the 11-50 employee band.
How does Checkpoint Therapeutics' funding compare to other Biotechnology startups?
Checkpoint Therapeutics' latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Checkpoint Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Checkpoint Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.